SCHEMBL10189237

SCHEMBL10189237

COc1ccc(-c2csnc2-c2cc(C)c(OC)c(OC)c2)cc1NC(C)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ADORA3 P0DMS8 5/20 0.43
ADORA2B P29275 1/20 0.43
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ABCB1 P08183 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
FYN P06241 2/20 0.38
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618841 0.94 ADORA3 (0.48) ALDH1A1MEN1KMT2AKDM4ENPC1
SCHEMBL10189445 0.88 NPSR1 (0.47) ALDH1A1MEN1KMT2AKDM4ENPC1
SCHEMBL10189378 0.88 LMNA (0.38) ALDH1A1LMNAADORA3ADORA2BMAPK1
SCHEMBL10189442 0.87 NPSR1 (0.41) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL10189439 0.87 NPSR1 (0.39) ALDH1A1MEN1KMT2AKDM4ENPC1
SCHEMBL10189449 0.86 SMN1; SMN2 (0.37) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL10189395 0.86 LMNA (0.37) ALDH1A1MEN1KMT2ALMNAADORA3
SCHEMBL10189390 0.86 LMNA (0.39) ALDH1A1MEN1KMT2ALMNAADORA3
SCHEMBL10189396 0.86 LMNA (0.37) ALDH1A1MEN1KMT2ALMNAADORA3
SCHEMBL10189391 0.86 LMNA (0.39) ALDH1A1MEN1KMT2ALMNAADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885MEN1 1571/4885KMT2A 2808/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885MEN1 1571/4885KMT2A 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.